Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Also discarded is belvarafenib (previously HM95573), a small-molecule pan-RAF inhibitor that was also in phase 1b testing as a solid tumour therapy. It was licensed from South Korea’s Hanmi ...

Under the agreement, Genentech will obtain exclusive worldwide rights outside South Korea, to develop and market Hanmi’s pan-RAF inhibitor HM95573. Hanmi will receive $80 million upfront ...

ALTA3263 is an oral KRAS-selective inhibitor specifically designed to potently inhibit the KRAS “ON” (active) state of greater than 90% of all KRAS mutations and to provide complete target ...

Combining avutometinib with a pan-RAF inhibitor (exarafenib or belvarafenib) led to strong tumor regressions in multiple NRAS- and BRAF-driven tumor models corresponding with nearly complete ...